FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Novalar Pharmaceuticals - Top 20 VC deals of 2007

Tools

Company: Novalar Pharmaceuticals
Based: San Diego, CA
Amount: $42
Round: Fourth
Investors: Domain Associates, Montreux Equity Partners, New Enterprise Associates, S.R. One, Undisclosed Venture Firm

Scoop: Novalar is focused on developing oral healthcare therapies. It's lead product--NV-101--is designed to reverse the lingering and debilitating lip and tongue numbness associated with local dental anesthesia. It was submitted to the FDA in June of 2007. The funding will help Novalar commercialize NV-101 if approved by the FDA.


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Biotech Venture Capital   Novalar Pharmaceuticals